Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 12 2021
Historique:
received: 17 05 2021
accepted: 13 08 2021
pubmed: 1 10 2021
medline: 8 1 2022
entrez: 30 9 2021
Statut: ppublish

Résumé

Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response to therapy and a low overall survival rate of approximately 30% after 5 years. We have analyzed a series of 105 cases with a diagnosis of PTCL using a customized NanoString platform (NanoString Technologies, Seattle, WA) that includes 208 genes associated with T-cell differentiation, oncogenes and tumor suppressor genes, deregulated pathways, and stromal cell subpopulations. A comparative analysis of the various histological types of PTCL (angioimmunoblastic T-cell lymphoma [AITL]; PTCL with T follicular helper [TFH] phenotype; PTCL not otherwise specified [NOS]) showed that specific sets of genes were associated with each of the diagnoses. These included TFH markers, cytotoxic markers, and genes whose expression was a surrogate for specific cellular subpopulations, including follicular dendritic cells, mast cells, and genes belonging to precise survival (NF-κB) and other pathways. Furthermore, the mutational profile was analyzed using a custom panel that targeted 62 genes in 76 cases distributed in AITL, PTCL-TFH, and PTCL-NOS. The main differences among the 3 nodal PTCL classes involved the RHOAG17V mutations (P < .0001), which were approximately twice as frequent in AITL (34.09%) as in PTCL-TFH (16.66%) cases but were not detected in PTCL-NOS. A multivariate analysis identified gene sets that allowed the series of cases to be stratified into different risk groups. This study supports and validates the current division of PTCL into these 3 categories, identifies sets of markers that can be used for a more precise diagnosis, and recognizes the expression of B-cell genes as an IPI-independent prognostic factor for AITL.

Identifiants

pubmed: 34592752
pii: 477109
doi: 10.1182/bloodadvances.2021005171
pmc: PMC8714715
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5588-5598

Informations de copyright

© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Histopathology. 2012 Mar;60(4):570-85
pubmed: 22251198
Nat Genet. 2014 Apr;46(4):329-35
pubmed: 24531327
Am J Hematol. 2019 Jun;94(6):628-634
pubmed: 30829413
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
J Clin Oncol. 2006 Jun 1;24(16):2472-9
pubmed: 16636342
Am J Surg Pathol. 2016 Mar;40(3):335-41
pubmed: 26574844
J Clin Invest. 2007 Mar;117(3):823-34
pubmed: 17304354
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
Oncotarget. 2017 Nov 30;8(67):111386-111395
pubmed: 29340061
Leuk Lymphoma. 2016 Nov;57(11):2489-98
pubmed: 27347699
Haematologica. 2020 Jun;105(6):1582-1592
pubmed: 31488561
Oncotarget. 2018 Mar 1;9(22):16124-16133
pubmed: 29662631
Exp Hematol Oncol. 2021 Feb 5;10(1):9
pubmed: 33546774
Appl Immunohistochem Mol Morphol. 2019 Jul;27(6):416-422
pubmed: 29629950
Exp Hematol Oncol. 2021 May 14;10(1):33
pubmed: 33990228
Blood. 2008 May 1;111(9):4463-70
pubmed: 18292286
Eur J Haematol. 2007 Apr;78(4):290-6
pubmed: 17378891
Int Immunol. 2015 Aug;27(8):393-404
pubmed: 25920998
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Blood. 2014 May 1;123(18):2893-4
pubmed: 24786457
Br J Haematol. 2021 Jan;192(1):82-99
pubmed: 32426847
Cancer Treat Res. 2019;176:31-68
pubmed: 30596212
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
J Clin Oncol. 2007 Aug 1;25(22):3321-9
pubmed: 17577022
Br J Haematol. 2018 Jun;181(6):760-769
pubmed: 29672827
J Clin Oncol. 2017 Jun 20;35(18):2008-2017
pubmed: 28459613
J Immunol. 2009 Oct 15;183(8):4994-5005
pubmed: 19801521
Blood. 2019 Dec 12;134(24):2159-2170
pubmed: 31562134

Auteurs

Marta Rodríguez (M)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.

Ruth Alonso-Alonso (R)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.

Laura Tomás-Roca (L)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

Socorro M Rodríguez-Pinilla (SM)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.

Rebeca Manso-Alonso (R)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

Laura Cereceda (L)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.

Jennifer Borregón (J)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

Teresa Villaescusa (T)

Lymphoma Unit, Department of Hematology, Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.

Raúl Córdoba (R)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Lymphoma Unit, Department of Hematology, Fundación Jiménez Díaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain.

Margarita Sánchez-Beato (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Ismael Fernández-Miranda (I)

Lymphoma Research Group, Medical Oncology Department, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Isabel Betancor (I)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.

Carmen Bárcena (C)

Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

Juan F García (JF)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Pathology Department, Hospital MD Anderson Cancer Center, Madrid, Spain.

Manuela Mollejo (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Pathology Department, Hospital Virgen de la Salud, Toledo, Spain.

Mónica García-Cosio (M)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Paloma Martin-Acosta (P)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
Pathology Department, Hospital Universitario Puerta de Hierro-Segovia de Arana, Madrid, Spain.

Fina Climent (F)

Pathology Department, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Dolores Caballero (D)

Haematology Department, Hospitalario Universitario de Salamanca (HUS/IBSAL), Salamanca, Spain.

Lorena de la Fuente (L)

Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.

Pablo Mínguez (P)

Bioinformatics Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Department of Genetics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain.

Linda Kessler (L)

Kura Oncology Inc., San Diego, CA; and.

Catherine Scholz (C)

Kura Oncology Inc., San Diego, CA; and.

Antonio Gualberto (A)

Kura Oncology Inc., San Diego, CA; and.

Rufino Mondéjar (R)

Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.
UGC Laboratorios, Hospital Universitario de Puerto Real, Cádiz, Spain.

Miguel A Piris (MA)

Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH